Investing.com - Financial Markets Worldwide
💎 Fed’s first rate cut since 2020 set to trigger market. Find undervalued gems with Fair ValueSee Undervalued Stocks

Dosing-finding study commences for Dimension Therapeutics' gene therapy candidate DTX301 in patients with urea cycle disorder; shares up 2%

Published 08/31/2017, 11:32 AM
© Reuters. Dosing-finding study commences for Dimension Therapeutics' gene therapy candidate DTX301 in patients with urea cycle disorder; shares up 2%
DMTX
-
  • Patient dosing is underway in a Phase 1/2 open-label, dose-finding trial assessing Dimension Therapeutics' (DMTX +2.4%) DTX301 in patients with Ornithine Transcarbamylase Deficiency, a genetic urea cycle disorder characterized by the buildup of ammonia in the blood.
  • The primary endpoint is safety as measured by the incidence of treatment-emergent adverse events. Secondary endpoints include efficacy measures of the change from baseline in ureagenesis rate and the change from baseline in the 24-hour area-under-the-curve of ammonia. According to ClinicalTrials.gov, the estimated primary completion date is November 2018.
  • DTX301 is an AAV gene therapy product designed to deliver ornithine transcarbamylase gene expression in a sustainable way.
  • Previously: REGENXBIO to acquire Dimension Therapeutics in all-stock deal, Dimension up 163% premarket (Aug. 25)
  • Now read: Regenxbio (RGNX) To Acquire Dimension Therapeutics (DMTX) - Slideshow


Original article

Latest comments

Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.